Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
Abstract Background Anti-CD19 CAR T cell therapy has demonstrated high response rates in patients with relapsed or refractory (r/r) B cell malignancies but is associated with significant toxicity. Cytokine release syndrome (CRS) is the most significant complication associated with CAR T cell therapy...
Main Authors: | David Porter, Noelle Frey, Patricia A. Wood, Yanqiu Weng, Stephan A. Grupp |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0571-y |
Similar Items
-
Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
by: D. Porter, et al.
Published: (2018-06-01) -
Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
by: Puri Ferreros, et al.
Published: (2022-07-01) -
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
by: Riegler LL, et al.
Published: (2019-02-01) -
Cytokine release syndrome
by: Alexander Shimabukuro-Vornhagen, et al.
Published: (2018-06-01) -
Severe acute heart failure during or following cytokine release syndrome after CAR T-cell therapy
by: Kyoko Yoshihara, et al.
Published: (2022-01-01)